EOS looks for MelaFind partners:
This article was originally published in Clinica
Executive Summary
Electro-Optical Sciences is seeking commercialisation partners for its hand-held melanoma scanner, which it anticipates launching in mid-2008, subject to US regulatory clearance. Its device, called MelaFind, is a noninvasive, point-of-care instrument that emits light of multiple wavelengths to capture images of suspicious pigmented skin lesions and extract data. Using algorithms, the data are then analysed against a proprietary database of melanomas and benign lesions to provide information to the physician, and produce a recommendation of whether the lesion should be biopsied. Patient accrual in a final blinded pivotal trial of the device is over 20% complete, said the Irvington, New York firm. Four pivotal study sites are active, and additional pivotal trial sites will be activated in the upcoming weeks.
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.